Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement

Diffuse large B-cell lymphoma (DLBCL), the most common type of human immunodeficiency virus (HIV)-related lymphoma, is associated with a high risk of central nervous system (CNS) involvement. Studies have shown that CD20×CD3 bispecific antibodies have significant therapeutic efficacy in refractory B-cell lymphoma. Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.